Dividend compounder review

EXEL

Exelixis Inc · NASDAQ · US

Healthcare · Biotechnology

Chart Factor Intelligence Back to Screener
Score60.50/100
Confidence82.00/100
DecisionInsufficient Data
RatingAvoid
Scoring

Quality breakdown

Dividend Reliability 0.0 / 25 Payment history, cuts, growth, and regularity.
Dividend Sustainability 14.0 / 20 Payout, free cash flow, dividend cover, and debt.
Business Quality 25.0 / 25 Scale, cash generation, growth, margins, and returns.
Valuation Discipline 8.0 / 15 Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend 13.5 / 15 Trend line, long return history, and drawdown control.
Metrics

Dividend and business context

Dividend Years0
Dividend Yield0.00%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income$782.6M
Free Cash Flow$844.3M
FCF Covers DividendUnknown
Debt / Equity8.76
P/E17.6
Revenue Growth 5Y18.6%
Net Margin35.1%
ROE41.0%
Price vs Trend18.3%
3Y Return167.5%
5Y Return126.9%
CurrencyUSD
Warnings

Review flags

No usable dividend history found.
Debt to equity is elevated at 8.76.
Dividend diary

Activity record

EXEL dividend review warning Warning · Warning

Debt to equity is elevated at 8.76.